The OBN Awards celebrate innovation and outstanding achievement across the UK Life Sciences industry, including emerging to late-stage R&D companies as well as life science investors
Synpromics was nominated for its work on gene control, improving human health by enabling safer, more effective cell and gene medicines and intelligent data-driven design. Achieved through its work in proprietary genomics and bioinformatics.
The Awards cover Biotech, Medtech, Synthetic Biology and Digital Health.
Michael Roberts, Founder & CSO of Synpromics, said: “We could not be happier with the outcome of last night’s Awards.
“This accolade is testament to the significant progress we have made over the past year, in growing our business by expanding the number of partnerships that we have with top pharma and biotech companies and significantly expanding our team.”